Tissue-specific promoters in gene therapy for the treatment of prostate cancer

T. Shirakawa, A. Gotoh, Y. Wada, S. Kamidono, S. C. Ko, C. Kao, T. A. Gardner, L. W.K. Chung

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Delivery of therapeutic toxic genes to and their expression in tumor cells through the use of tissue-specific promoters could decrease their toxic effect on neighboring normal cells when virus-mediated gene delivery results in their infection. We have demonstrated the utility of two prostate cancer- specific promoters, long PSA and osteocalcin, for tissue-specific toxic gene therapy for prostate cancer. The two promoters were highly active in both androgen-dependent and androgen-independent prostate cancer cells. We also introduce the Phase I trial of osteocalcin promoter-based toxic gene therapy for bone metastases of prostate cancer, which is in progress at the University of Virginia.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalMolecular Urology
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Tissue-specific promoters in gene therapy for the treatment of prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Shirakawa, T., Gotoh, A., Wada, Y., Kamidono, S., Ko, S. C., Kao, C., Gardner, T. A., & Chung, L. W. K. (2000). Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Molecular Urology, 4(2), 73-82. https://doi.org/10.1089/10915360050138620